Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 25.50
Bid: 25.00
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 1.00 (4.00%)
Open: 25.50
High: 25.50
Low: 25.50
Prev. Close: 25.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Mar 2024 14:52

RNS Number : 7759I
Renalytix PLC
28 March 2024
 

 

Please note that from 22 March 2021, the Standard TR-1 Form should be completed and submitted to the FCA via our Electronic Submission System (ESS) in relation to notifications of voting rights held in issuers whose shares are admitted to trading on UK regulated markets.

 

Holders of voting rights in issuers whose shares are admitted to trading on UK prescribed markets such as AIM market, can continue to use this form to send their notifications to those issuers. Alternatively, if they wish they can register on ESS to be able to notify to us, produce a TR-1 Form via ESS and submit the downloaded version to issuers with shares admitted to trading on prescribed markets.

 

More information on how to submit a TR-1 Form via ESS is available here

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Renalytix plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

CVI Holdings, LLC

City and country of registered office (if applicable)

1201 N. ORANGE STREET, SUITE 715

WILMINGTON, DE 19801

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

12/03/2024

6. Date on which issuer notified (DD/MM/YYYY):

14/03/2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

3.54%

0%

3.54%

4,250,000

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYWL4Y04

0

4,250,000

0.00%

3.54%

SUBTOTAL 8. A

4,250,000

3.54%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

CVI Holdings, LLC.

CVI Investments, Inc.

3.54%

0%

3.54%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

401 City Ave Suite 220, Bala Cynwyd, PA 19004

Date of completion

27/03/2024

 

 

 

 

 

Notes

 

i Please note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link: https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only in this way will the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain by numbering each chain accordingly. Please see the below example: 

Name of ultimate controlling person A (chain 1)

Name of controlled undertaking B

Name of controlled undertaking C

Name of ultimate controlling person A (chain 2)

Name of controlled undertaking B

Name of controlled undertaking D

Name of ultimate controlling person A (chain3)

Name of controlled undertaking E

Name of controlled undertaking F

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFESVIITFIS
Date   Source Headline
21st May 20217:02 amRNSDirector/PDMR Dealing
19th May 20218:00 amRNSPartnership
22nd Apr 20212:06 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 202111:05 amRNSSecond Price Monitoring Extn
22nd Apr 202111:00 amRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNS10-year US Government contract award
20th Apr 20217:00 amRNSPositive clinical outcome data for KidneyIntelX
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
14th Apr 20217:00 amRNSExclusive option agreement
8th Apr 20217:00 amRNSClinical Utility Study
6th Apr 20217:00 amRNSClinical findings published in Diabetologia
15th Mar 20217:00 amRNSUpdate on Finalization of MCIT Rule
4th Mar 20216:00 pmRNSIssue of shares, PDMR Dealing and TVR
2nd Mar 20217:02 amRNSFinancial Results for Second Quarter of FY 2021
2nd Mar 20217:00 amRNSHalf-year Report
24th Feb 20217:00 amRNSUniversity of Utah Kidney Health Partnership
23rd Feb 20217:00 amRNSNotice of Results
4th Feb 20217:00 amRNSASN & Renalytix to Co-Host Capital Markets Day
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20217:00 amRNSFinalization of MCIT rule for coverage pathway
5th Jan 20214:41 pmRNSSecond Price Monitoring Extn
5th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPartnership Between RenalytixAI and DaVita
4th Jan 20217:00 amRNSRENX to present at 39th JP Morgan Healthcare Conf.
7th Dec 20203:45 pmRNSResult of AGM
2nd Dec 20201:08 pmRNSPartnership with National Kidney Foundation
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:35 pmRNSPrice Monitoring Extension
25th Nov 20207:00 amRNSFinancial Results for First Quarter of FY 2021
13th Nov 20207:00 amRNSStifel 2020 Healthcare Conference
6th Nov 20207:00 amRNSChange of Adviser
2nd Nov 20203:30 pmRNSPosting of Annual Report & Accounts &Notice of AGM
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
27th Oct 20207:00 amRNSFull Year Report
20th Oct 202012:00 pmRNSSchedule One - Verici Dx PLC
16th Oct 20207:00 amRNSNotice of Results
13th Oct 20203:32 pmRNSVerici Dx - Intention to admit to trading on AIM
22nd Sep 20207:00 amRNSCalifornia Commercial Lab Certification Recieved
18th Sep 20207:00 amRNSKidneyIntelX clinical testing launch
2nd Sep 20207:00 amRNSGrant of Purchase Rights and Verici update
26th Aug 20207:00 amRNSSubmission seeking FDA Clearance of KidneyIntelX
21st Aug 20208:00 amRNSRenalytixAI to Collaborate with AstraZeneca
3rd Aug 20207:00 amRNSKidneyIntelX in Multi-Center Study
31st Jul 20204:31 pmRNSTotal Voting Rights
27th Jul 20207:00 amRNSOver allotment option exercise
21st Jul 20205:30 pmRNSClosing of Global Offering and resulting TVR
17th Jul 20207:00 amRNSPricing of Global Offering

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.